Loading cancer entity…
Loading cancer entity…
Clinical trials
210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (37)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05932758 | Excisional Vacuum-Assisted Breast Biopsy | unknown | N/A | 300 | European Institute of OncologyOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05868252 |
| Molecular Analysis of the Sloane Project |
| unknown |
| — |
| 1,500 |
| King's College LondonOTHER |
| 1 |
| May 22, 2023 |
| clinicaltrials |
| NCT00470236 | Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast(DCIS) | unknown | N/A | 1,608 | Trans Tasman Radiation Oncology GroupOTHER | 11 | Mar 22, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT02909426 | The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness(MUST-BE) | unknown | — | 11,880 | Soonchunhyang University HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT03109522 | Axillary Reverse Mapping (ARM) Technique(ARM) | unknown | N/A | 130 | McMaster UniversityOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04046159 | Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ | unknown | Phase 3 | 810 | National Taiwan University HospitalOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT04021069 | Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer | unknown | — | 800 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03543397 | MRI in Ductal Carcinoma in Situ (DCIS) | unknown | — | 74 | University Hospital, Strasbourg, FranceOTHER | 1 | Jun 1, 2018 | clinicaltrials |
| NCT01038258 | Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy(PETBreast) | unknown | N/A | 80 | Auxilio Mutuo Cancer CenterOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT01484704 | The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer | unknown | — | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 2, 2011 | clinicaltrials |
| NCT01126138 | Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) | unknown | Phase 3 | 200 | Chinese Academy of Medical SciencesOTHER | 1 | May 4, 2011 | clinicaltrials |
| NCT00669747 | Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) | unknown | Phase 2 | 45 | Windy Hill Medical, Inc.INDUSTRY | 1 | Oct 2, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2024source: clinicaltrials